Verastem submits NDA to FDA for duvelisib

Verastem Inc. (NASDAQ:VSTM) submitted an NDA to FDA for duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic

Read the full 189 word article

User Sign In